DORCHESTER, MA, United States
DORCHESTER, MA, United States

Time filter

Source Type

Patent
Eutropics Pharmaceuticals, Inc. | Date: 2015-02-17

The invention relates to a chemotherapeutic cancer treatment in which compounds (BH3Is) are administered to a mammal to treat B-cell Lymphoma or other hematopoietic cancers, including diseases associated with MCL-1. The invention also provides a method for treating types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more disclosed compounds in combination with other therapes, for example, 26S proteasome inhibitors, such as, for example, Bortezomib. The invention also relates to autoimmune treatment with pharmaceutical compositions comprising one or more disclosed compounds. The invention also relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease. Illustrative compounds are those of Formula II:


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 1.50M | Year: 2012

There is a clear need to better define patient-specific treatment strategies for the use of both standard and novel therapies for treating Multiple Myeloma (MM) both to improve efficacy and reduce unnecessary side effects. Eutropics Pharmaceuticals is uniquely positioned to improve therapy efficacy for MM by using a proprietary assay that provides a novel predictive biomarker, BH3 profiling. The assay uniquely assesses mitochondrial functionality in cancer cells. This technology is proven in a patient testset to predict the patient responsiveness to standard treatments for MM. In this phase 2 contract Eutropics will establish and deliver a refined standard operating protocol for the BH3 profiling assay and a CLlA 88 approval. Biopsied MM patient samples continue to be obtained from several academic cancer centers and pharmaceutical companies under collaboration agreements. Further partnering with additional pharmaceutical companies will be established during this contract. A verification data set will be collected. From this the specificity and sensitivity of the assay and assay cutoffs will be established. A validation study in uniformly treated clinical trials patients will follow. Completion of this study will fulfill the contract.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 1.50M | Year: 2014

Not Available


Patent
Eutropics Pharmaceuticals, Inc. | Date: 2014-07-18

The present invention relates to methods of determining cancer cell sensitivity to treatment by correlating the pattern of sensitivity of the cell to a panel of BH3 domain peptides. The invention also provides a method applying an algorithm to said pattern to predict therapeutic efficacy and of monitoring the shift in cell sensitivity to a therapeutic during treatment.


Patent
Eutropics Pharmaceuticals, Inc. | Date: 2014-08-01

The present invention relates to methods of determining cancer cell sensitivity to treatment by using antibodies to detect the presence of heterodimers comprising Bcl-2 proteins or caspase-IAP proteins in the cell. The invention also provides a method of predicting therapeutic efficacy in a cancer patient.


Patent
Eutropics Pharmaceuticals, Inc. | Date: 2014-10-30

The present disclosure relates to diagnostic methods that are relevant to various cancers and which comprise BH3 profiling diagnostics for, among others, predication of an adverse patient response to a cancer treatment.


The present invention relates to compositions and methods for cancer treatment comprising compounds of Formulae I, II, and III. In some aspects, the invention relates to the treatment of B-cell Lymphoma or other hematopoietic cancers. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as, for example, B-cell lymphoma, using a combination of one or more compounds of Formulae I, II, and III. Combination therapy with, for example, 26S proteasome inhibitors, such as, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formulae I, II, and III. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.


Patent
Eutropics Pharmaceuticals, Inc. | Date: 2015-04-30

The present invention relates to a compositions for and methods of cancer treatment in which compounds of Formula I or Formula II. In some aspects, the treatment of B-cell Lymphoma or other hematopoietic cancers is encompassed. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds of Formula I or Formula II. Combination therapy with, for example, a class of therapeutics known as 26S proteasome inhibitors, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formula I or Formula II. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.


The present invention relates to compositions and methods for cancer treatment comprising compounds of Formulae I, II, and III. In some aspects, the invention relates to the treatment of B-cell Lymphoma or other hematopoietic cancers. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as, for example, B-cell lymphoma, using a combination of one or more compounds of Formulae I, II, and III. Combination therapy with, for example, 26S proteasome inhibitors, such as, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formulae I, II, and III. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.


Patent
Eutropics Pharmaceuticals, Inc. | Date: 2014-04-30

Isolated antibodies specifically binding to heterodimers of the Bcl-2 family and uses thereof for detecting presence of Bcl-2 heterodimers in a patient.

Loading Eutropics Pharmaceuticals, Inc. collaborators
Loading Eutropics Pharmaceuticals, Inc. collaborators